Shanghai Launches Inhalation Vaccination for New Crown Vaccine Consino Biologicals Once Jumped 18 Percent

Read Time:1 Minute, 48 Second

Following the news of Shanghai’s launch of the booster vaccination for the new crown vaccine by inhalation, shares of Concino Biologics (06185.HK) strengthened again today after yesterday’s late surge, and once jumped 18% during the day. As of press time, the share price of Conviviality rose 16.65% to HK$62.

According to the news released by the official WeChat of “Shanghai Release” at 15:28 on Tuesday afternoon, Shanghai started to register for booster immunization with recombinant new coronavirus vaccine (type 5 adenovirus vector) for inhalation on the 25th, and started the booster immunization today.

“The official WeChat also mentioned that people aged 18 and above who have previously received the full course of the New Coronavirus vaccine (type 5 adenovirus vector) for six months can choose to receive a booster dose of the recombinant New Coronavirus vaccine (type 5 adenovirus vector) for inhalation. The booster vaccination is free of charge.

Buoyed by the above news, Concierge Biologics, which has the inhaled Neoconazole vaccine, closed up 8.91% on the 25th.

Note: The trend of Concierto Bio H shares since Oct. 25

Concino’s inhaled Neocrown vaccine was previously included in emergency use

The inhalation Neocrown vaccine of Concierto Biologics has completed the phase I and II clinical trials last year. At that time, Zhu Tao, chief scientific officer of Consino Bio, said that Consino Bio’s world’s first inhaled Neocrown vaccine, which used the same vaccine as intramuscular injection, had not changed its formulation but only used a different delivery method.

Note: Announcement by Consino Biologics on September 5

Subsequently, in early September this year, Kangxino Bio released that the recombinant novel coronavirus vaccine for inhalation (inhalation new crown vaccine) developed by the company had been recommended by the National Health and Health Commission, and the State Drug Administration had organized a demonstration and agreed to be included as a booster shot for emergency use.

ZSE Securities recently pointed out that the recombinant novel coronavirus vaccine for inhalation by KangXinuo Bio was included in the emergency use as a booster shot, which is bullish on the growth potential of the company under the approval of the product.